High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma

Int J Cancer. 2002 Feb 1;97(4):432-8. doi: 10.1002/ijc.1636.

Abstract

Matrix metalloproteinases (MMPs) are proteolytic enzymes capable of degrading extracellular matrix. Their role has been emphasized in tumor invasion, metastasis and tumor-induced angiogenesis. We studied the expression of collagenase-1 (MMP-1), stromelysin-1 (MMP-3) and collagenase-3 (MMP-13) in 70 melanoma metastases obtained from 56 patients treated with combined chemoimmunotherapy. The patients were divided into 2 groups using a cut-off point of 0% for MMP-1 expression and 20% for MMP-3 expression. We found that patients with MMP-1 positive metastases (n = 38) had significantly shorter disease-free survival compared to patients with MMP-1 negative metastases (n = 18) (median 11.2 vs. 17.0 months, p = 0.0383). The disease-free survival of patients with high levels of MMP-3 expression in their metastases (> or = 20% positive tumor cells, n = 14) was also significantly shorter compared to patients with lower levels of expression (n = 42) (median 5.1 vs. 14.0 months, p = 0.0294). The expression of MMP-13 did not correlate to survival parameters. We also found that the presence of melanin, a pigment produced by melanocytes, correlated with high expression levels of MMP-1 (p = 0.0002), MMP-3 (p < 0.0001) and MMP-13 (p = 0.0009). The high expression levels of MMP-13 were also associated with the presence of visceral metastases (p = 0.0284). Our findings suggest that MMP-1 and -3 may have a special role in melanoma metastasis formation and thus they could be used to measure the biological activity of the disease.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / administration & dosage
  • Cell Division
  • Collagenases / biosynthesis*
  • Collagenases / genetics
  • Combined Modality Therapy
  • Dacarbazine / administration & dosage
  • Disease-Free Survival
  • Enzyme Induction
  • Female
  • Humans
  • Immunologic Factors / therapeutic use
  • Immunotherapy
  • Interferon-alpha / therapeutic use
  • Interleukin-2 / therapeutic use
  • Lomustine / administration & dosage
  • Male
  • Matrix Metalloproteinase 3 / biosynthesis*
  • Matrix Metalloproteinase 3 / genetics
  • Melanins / analysis
  • Melanocytes / enzymology
  • Melanoma / blood supply
  • Melanoma / drug therapy
  • Melanoma / enzymology
  • Melanoma / mortality
  • Melanoma / secondary*
  • Melanoma / therapy
  • Middle Aged
  • Neoplasm Proteins / biosynthesis*
  • Neoplasm Proteins / genetics
  • Neoplastic Stem Cells / enzymology
  • Prognosis
  • Radiotherapy, Adjuvant
  • Vincristine / administration & dosage

Substances

  • Immunologic Factors
  • Interferon-alpha
  • Interleukin-2
  • Melanins
  • Neoplasm Proteins
  • Bleomycin
  • Vincristine
  • Lomustine
  • Dacarbazine
  • Collagenases
  • collagenase 1
  • Matrix Metalloproteinase 3

Supplementary concepts

  • BOLD protocol